Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letter to the Editor

Telomere Length and Pancreatic Cancer Risk—Reply

Samuel O. Antwi, Lisa A. Boardman and Gloria M. Petersen
Samuel O. Antwi
1Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa A. Boardman
2Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gloria M. Petersen
3Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: petersen.gloria@mayo.edu
DOI: 10.1158/1055-9965.EPI-17-0307
  • Article
  • Info & Metrics
  • PDF
Loading

Our report (1) showed that genetic risk scores computed from polymorphic variants previously associated with interindividual variation in leukocyte telomere length (2–4) are not associated with risk of pancreatic cancer (pancreatic ductal adenocarcinoma). Consistent with our finding, a recent meta-analysis that used methods similar to ours (published while our manuscript was under review) found no association between genetically predicted telomere length and pancreatic cancer risk (5). We are not aware of any other published reports on the association between genetically predicted telomere length and pancreatic cancer risk.

The author referred to a study by Lynch and colleagues (6) and others (7, 8) and concluded that longer telomere length is associated with an increase in risk of pancreatic cancer. We would like to point out that while Lynch and colleagues directly measured leukocyte telomere length using monochrome quantitative multiplex PCR (6), we used genotypes to predict telomere length, as has been done by others (5, 9). Therefore, the two studies are not directly comparable. Measured telomere length reflects inherited genetic factors, aging, lifestyle (e.g., tobacco smoking), and chronic conditions, such as diabetes mellitus (10). Our study sought to delineate the role of the genetic component alone, which is estimated to account for up to 80% of interindividual differences in telomere length (10). The study by Lynch and colleagues would have reflected the genetic and the environmental components, age-related telomere attrition, and effect of other exposures that influence telomere length. It should be noted, however, that results from studies involving measured leukocyte telomere length have varied widely.

In contrast to Lynch and colleagues, who studied Finnish males who smoked five or more cigarettes a day (6), Bao and colleagues recently performed a pooled analysis of five prospective studies in the United States and found that short, rather than long, leukocyte telomere length is associated with an increase in risk of pancreatic cancer in a dose–response fashion (11). Furthermore, a prospective cohort study in China found a “U-shaped” association between leukocyte telomere length and pancreatic cancer risk (12), as did a clinic-based case–control in the United States (13). A study of the European Prospective Investigation into Cancer and Nutrition (EPIC) found no significant association between leukocyte telomere length and pancreatic cancer; however, in a secondary analysis using cubic spline regression, the investigators found evidence for a nonlinear relationship (14).

Although it is plausible that leukocyte telomere length represents an integrative molecular marker of exposure to risk factors for pancreatic cancer, the current evidence precludes definitive conclusions. Potential reasons for the discrepancy in study findings have been discussed (1). We agree that the potential roles of telomerase and survivin in telomere lengthening and inhibition of apoptosis to promote carcinogenesis should be explored further in both tumor- and blood-based studies for new insights into telomere dynamics in pancreatic cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received March 30, 2017.
  • Revision received March 31, 2017.
  • Accepted April 3, 2017.
  • ©2017 American Association for Cancer Research.

References

  1. 1.↵
    1. Antwi SO,
    2. Bamlet WR,
    3. Broderick BT,
    4. Chaffee KG,
    5. Oberg AL,
    6. Jatoi A,
    7. et al.
    Genetically predicted telomere length is not associated with pancreatic cancer risk. Cancer Epidemiol Biomark Prev 2017;26:971–4.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Codd V,
    2. Nelson CP,
    3. Albrecht E,
    4. Mangino M,
    5. Deelen J,
    6. Buxton JL,
    7. et al.
    Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013;45:422–7.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Pooley KA,
    2. Bojesen SE,
    3. Weischer M,
    4. Nielsen SF,
    5. Thompson D,
    6. Amin Al Olama A,
    7. et al.
    A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet 2013;22:5056–64.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Mangino M,
    2. Hwang SJ,
    3. Spector TD,
    4. Hunt SC,
    5. Kimura M,
    6. Fitzpatrick AL,
    7. et al.
    Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet 2012;21:5385–94.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Haycock PC,
    2. Burgess S,
    3. Nounu A,
    4. Zheng J,
    5. Okoli GN,
    6. Bowden J,
    7. et al.
    Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017;3:636–51.
    OpenUrl
  6. 6.↵
    1. Lynch SM,
    2. Major JM,
    3. Cawthon R,
    4. Weinstein SJ,
    5. Virtamo J,
    6. Lan Q,
    7. et al.
    A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. Int J Cancer 2013;133:2672–80.
    OpenUrlPubMed
  7. 7.↵
    1. Dong H,
    2. Qian D,
    3. Wang Y,
    4. Meng L,
    5. Chen D,
    6. Ji X,
    7. et al.
    Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol 2015;13:189.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Endoh T,
    2. Tsuji N,
    3. Asanuma K,
    4. Yagihashi A,
    5. Watanabe N
    . Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005;305:300–11.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Zhang C,
    2. Doherty JA,
    3. Burgess S,
    4. Hung RJ,
    5. Lindström S,
    6. Kraft P,
    7. et al.
    Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum Mol Genet 2015;24:5356–66.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Blackburn EH,
    2. Epel ES,
    3. Lin J
    . Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science 2015;350:1193–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Bao Y,
    2. Prescott J,
    3. Yuan C,
    4. Zhang M,
    5. Kraft P,
    6. Babic A,
    7. et al.
    Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut 2017;66:1116–22.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Zhang R,
    2. Zhao J,
    3. Xu J,
    4. Liu F
    . Association of peripheral leukocyte telomere length and its variation with pancreatic cancer and colorectal cancer risk in Chinese population. Oncotarget 2016;7:38579–85.
    OpenUrl
  13. 13.↵
    1. Skinner HG,
    2. Gangnon RE,
    3. Litzelman K,
    4. Johnson RA,
    5. Chari ST,
    6. Petersen GM,
    7. et al.
    Telomere length and pancreatic cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 2012;21:2095–100.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Campa D,
    2. Mergarten B,
    3. De Vivo I,
    4. Boutron-Ruault MC,
    5. Racine A,
    6. Severi G,
    7. et al.
    Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2014;23:2447–54.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

This OnlineFirst version was published on June 20, 2017
doi: 10.1158/1055-9965.EPI-17-0307

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Telomere Length and Pancreatic Cancer Risk—Reply
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Telomere Length and Pancreatic Cancer Risk—Reply
Samuel O. Antwi, Lisa A. Boardman and Gloria M. Petersen
Cancer Epidemiol Biomarkers Prev June 20 2017 DOI: 10.1158/1055-9965.EPI-17-0307

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Telomere Length and Pancreatic Cancer Risk—Reply
Samuel O. Antwi, Lisa A. Boardman and Gloria M. Petersen
Cancer Epidemiol Biomarkers Prev June 20 2017 DOI: 10.1158/1055-9965.EPI-17-0307
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Aspirin and Prostate Cancer Incidence and Mortality—Letter
  • NSAID Use and Colorectal Cancer—Letter
  • TSH, Thyroid Hormone, and PTC—Letter
Show more Letter to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement